Biotii Technologies develops genetically engineered microorganisms to produce cannabinoids (including THC and CBD) and other target drug molecules via biosynthesis. The company is building an IP portfolio that includes synthetic cannabinoids, designer enzymes, a proprietary enzyme pathway, and GMO microorganisms. Biotii says its scalable synthesizing process will enable pharmaceutical-grade purities, stable yields, and materially lower production costs versus conventional cultivation and extraction. The team plans to implement food and pharmaceutical-grade GMP practices while scaling biosynthesis to thousands of liters in a semi/continuous environment. Biotii aims to establish processes by 2020 to mass-produce CBD/THC in quantities of hundreds of metric tons per annum. The company has forged research relationships in the United States and China and is led by a team with MIT/Harvard and other academic and medical backgrounds. The company is privately held and based in Boston, Massachusetts, USA.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2019